Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2024

Cash, cash equivalents and short-term investments for the periods presented consist of the following (in thousands):


	As of
	September 30, 2024		December 31, 2023
Cash	$	25,853	$	8,247
Money market funds		12,070		9,685
US treasury bills		6,980		12,594
Government-sponsored enterprise securities		8,484		11,233
Corporate bonds and commercial paper		7,727		15,174
	$	61,114	$	56,933
Reported as:
Cash and cash equivalents	$	51,692	$	32,786
Short-term investments		9,422		24,147
	$	61,114	$	56,933

Cash equivalents and short-term investments include the following securities with gross unrealized gains and losses (in thousands):


			Gross		Gross
	Amortized		Unrealized		Unrealized
As of September 30, 2024	Cost		Gains		Losses		Fair Value
US treasury bills	$	6,979	$	1	$	—	$	6,980
Government-sponsored enterprise securities		8,483		1		—		8,484
Corporate bonds and commercial paper		7,718		9		—		7,727
Total	$	23,180	$	11	$	—	$	23,191


			Gross		Gross
	Amortized		Unrealized		Unrealized
As of December 31, 2023	Cost		Gains		Losses		Fair Value
US treasury bills	$	12,591	$	3	$	—	$	12,594
Government-sponsored enterprise securities		11,230		7		(4)		11,233
Corporate bonds and commercial paper		15,172		5		(3)		15,174
Total	$	38,993	$	15	$	(7)	$	39,001